Table 1.
Characteristics of HIV‐positive adults initiating antiretroviral treatment in HIV clinics participating to the IeDEA West Africa collaboration 2002 to 2018 (N = 71,283)
| Men (N = 24,390) | Women (N = 46,893) | p‐value | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Median age at baseline (year) (IQR) | 40.8 (35.1 to 47.2) | 34.1 (28.9 to 40.7) | <0.001 a | ||
| Age at Baseline (years) | |||||
| 16 to 30 | 2194 | 9.0 | 14140 | 30.2 | <0.001 b |
| 30 to 40 | 9107 | 37.3 | 19930 | 42.5 | |
| >40 | 13089 | 53.7 | 12823 | 27.3 | |
| Median CD4 cell count (Cells/µL) (IQR) | 140 (55 to 250) | 184 (86 to 301) | <0.001 a | ||
| Baseline CD4 cell count (Cells/µL) | |||||
| <100 | 6566 | 38.3 | 9449 | 28.1 | <0.001 b |
| 100 to 199 | 4536 | 26.5 | 8547 | 25.4 | |
| 200 to 349 | 3988 | 23.3 | 9454 | 28.1 | |
| 350 to 499 | 1215 | 7.1 | 3295 | 9.8 | |
| ≥500 | 817 | 4.8 | 2913 | 8.7 | |
| Unknown (%) | 7268 (29.8) | 13235 (28.2) | |||
| Year of ART initiation | |||||
| Prior to 2006 | 6064 | 24.9 | 10873 | 23.2 | 0.0143 b |
| 2006 to 2010 | 13630 | 55.9 | 26340 | 56.2 | |
| 2011 to 2014 | 4696 | 19.3 | 9680 | 20.6 | |
| Initial ART regimen | |||||
| 2 NRTIs +1 PI | 2625 | 10.8 | 4477 | 9.5 | <0.001 b |
| 2 NRTIs + EFV | 11219 | 46.0 | 15477 | 33.0 | |
| 2 NRTIs + NVP | 9914 | 40.6 | 25898 | 55.2 | |
| Other | 632 | 2.6 | 1041 | 2.2 | |
| Body mass index | |||||
| Low weight | 2362 | 27.5 | 5628 | 31.5 | <0.001 b |
| Normal | 5053 | 58.7 | 9272 | 51.9 | |
| Overweight | 1189 | 13.8 | 2981 | 16.7 | |
| Unknown (%) | 15786 (64.7) | 29012 (61.9) | |||
| Baseline clinical stage | |||||
| CDC A/B. WHO I/II | 2669 | 49.6 | 6302 | 55.9 | <0.001 b |
| CDC C. WHO III/ IV | 2711 | 50.4 | 4970 | 44.1 | |
| Unknown (%) | 19010 (77.9) | 35621 (76.0) | |||
a
p‐value from Wilcoxon rank sum test.
b
p‐value from Fisher’s exact test.